Skip to main content
. Author manuscript; available in PMC: 2012 Dec 5.
Published in final edited form as: Virology. 2011 Oct 5;421(1):19–27. doi: 10.1016/j.virol.2011.09.014

Figure 5.

Figure 5

Erlotinib increases expression of HPV-16 E6/E7 RNAs in cervical cells. A. Real time PCR analysis of HPV-16 E6 and E7 RNAs in cells that were transfected with HPV-16 and then treated with erlotinib at 0.1 or 1.0 μM for 24 or 72 hours. Cells were treated with 3ng/ml TGF-β1 as a positive control. Bars represent the mean of two independent experiments ± standard error, and asterisks are values that differ statistically (p ≤ 0.05) from controls. B. Reporter gene assay to measure activity of HPV-16 LCR in cervical cells after treatment with various concentrations of erlotinib for 6, 24 or 48 hours. Points represent the mean of 3 wells ± standard error.